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Abstract 
 
Although multiple susceptibility loci for late-onset Alzheimer’s disease (LOAD) have been identiﬁed, 
a large portion of the genetic risk for this disease remains unexplained. LOAD risk may be associated 
with single-nucleotide polymorphisms responsible for changes in gene expression (eSNPs). To detect 
eSNPs associated with LOAD, we integrated data from LOAD genome-wide association studies and 
expression quantitative trait loci using Sherlock (a Bayesian statistical method). We identiﬁed a cis-
regulatory eSNP (rs2927438) located on chromosome 19q13.32, for which subsequent analyses 
conﬁrmed the association with both LOAD risk and the expression level of several nearby genes. 
Importantly, rs2927438 may represent an APOE-independent LOAD eSNP according to the weak 
linkage disequilibrium of rs2927438 with the 2 polymorphisms (rs7412 and rs429358) deﬁning the 
APOE-ε2, -ε3, and -ε4 alleles. Furthermore, rs2927438 does not inﬂuence chromatin interaction 
events at the APOE locus or cis-regulation of APOE expression. Further exploratory analysis revealed 
that rs2927438 is signiﬁcantly associated with tau levels in the ce-rebrospinal ﬂuid. Our ﬁndings 
suggest that rs2927438 may confer APOE-independent risk for LOAD. 
 
1. Introduction 
Alzheimer’s disease (AD) is a neurodegenerative disease primarily affecting the elderly that 
manifests through memory and cognitive decline. The hallmark features of the disease include the 
accumulation of amyloid plaques, tau neuroﬁbrillary tangles, and neuronal destruction, leading to 
brain atrophy. Currently, the pro-cesses leading to the formation of these neuronal lesions are not 
well understood (Small and Duff, 2008). Twin studies indicate that susceptibility alleles contribute as 
much as 79% to late-onset AD (LOAD) cases (Gatz et al., 2006), and genetic variance analyses 
estimate >53% of the variance in LOAD status can be explained by common variants with a minor 
allele frequency >1% (Ridge et al., 2016). 
With the advance of genome-wide association studies (GWASs), more than 20 loci have been reliably 
associated with risk for LOAD (Escott-Price et al., 2014; Guerreiro et al., 2013; Harold et al., 2009; 
Hollingworth et al., 2011; Jonsson et al., 2013; Lambert et al., 2009, 2013; Naj et al., 2011; Seshadri 
et al., 2010; Sims et al., 2017). APOE on chromosome 19q13.32 showed the strongest and most 
consis-tent evidence for association with LOAD. The 2 single-nucleotide polymorphisms (SNPs) in 
APOE (rs429358, rs7412) are underlying the ε2, ε3, and ε4 alleles. However, these polymorphisms 
are not reliably detected in the genome-wide arrays due to high GC content, and its genotyping 
requires special conditions, which complicates the assessment of linkage disequilibrium (LD) 
structure of APOE region in GWASs (Ghani et al., 2015). The ε4 allele increases LOAD risk in a dose-
dependent fashion (odds ratio (OR) ¼ 3 for estimate >53% of the variance in LOAD status can be 
explained by common variants with a minor allele frequency >1% (Ridge et al., 2016). 
With the advance of genome-wide association studies (GWASs), more than 20 loci have been reliably 
associated with risk for LOAD (Escott-Price et al., 2014; Guerreiro et al., 2013; Harold et al., 2009; 
Hollingworth et al., 2011; Jonsson et al., 2013; Lambert et al., 2009, 2013; Naj et al., 2011; Seshadri 
et al., 2010; Sims et al., 2017). APOE on chromosome 19q13.32 showed the strongest and most 
consis-tent evidence for association with LOAD. The 2 single-nucleotide polymorphisms (SNPs) in 
APOE (rs429358, rs7412) are underlying the ε2, ε3, and ε4 alleles. However, these polymorphisms 
are not reliably detected in the genome-wide arrays due to high GC content, and its genotyping 
requires special conditions, which complicates the assessment of linkage disequilibrium (LD) 
structure of APOE region in GWASs (Ghani et al., 2015). The ε4 allele increases LOAD risk in a dose-
dependent fashion (odds ratio (OR) ¼ 3 for heterozygotes) and signiﬁcantly lowers the age at onset 
(AAO), whereas the ε2 allele confers a protective beneﬁt(Corder et al., 1993, 1994). Previous studies 
suggested that other genetic vari-ability within the APOE locus may exist, such as modiﬁers of the 
level of expression of APOE alleles (Lambert et al., 1997). 
Due to the strong impact of APOE, it is difﬁcult to determine if additional loci on chromosome 
19q13.32 also contribute to LOAD (Jun et al., 2012; Perez-Palma et al., 2014). Several SNPs located in 
this region have been shown to be associated with LOAD due to strong LD with the APOE locus 
(Hollingworth et al., 2011; Naj et al., 2011; Seshadri et al., 2010). In models adjusting for APOE ε4, no 
SNPs in the extended APOE region were signiﬁcantly associated with LOAD (Jun et al., 2012). 
However, it is important to explore whether this genomic region contains functional APOE-indepen-
dent variation(s) that also confer risk for LOAD. 
Although multiple LOAD risk loci have been identiﬁed, the genes or DNA functional elements 
through which the risk variants of LOAD exert their effects on disease remain largely unknown. 
Accumulating evidence has demonstrated that changes in gene expression may play a key role in the 
pathogenesis of LOAD, and SNPs that inﬂuence LOAD risk may be responsible for changes in gene 
expression (Webster et al., 2009; Zou et al., 2010). Accordingly, recent studies have used integrative 
strategies to combine results from GWASs and expression quantitative trait loci (eQTL) data to 
identify novel potential risk genes (Ramasamy et al., 2014; Schadt et al., 2005). However, there is no 
study that systematically inte-grated eQTL data and GWASs of LOAD to identify functional risk 
variants (called eSNPs). Here, we ﬁrst used the Sherlock algorithm to integrate eQTL data from 
lymphoblastoid cell lines (LCLs) derived from peripheral blood samples (N ¼ 400) (Dixon et al., 2007) 
as well as association data from a large GWAS for LOAD (Naj et al., 2011) and reported a novel risk 
eSNP, rs2927438, on chromosome 19q13.32, acting indepen-dently of APOE (Fig. 1). To further 
characterize the potential role of rs2927438 in LOAD etiology, we conducted follow-up analyses in 
independent gene expression and large-scale GWAS data sets. Moreover, we assessed the 
association between rs2927438 and several endophenotypes, including hippocampal volume, as well 
as Ab42, tau and phosphorylated tau (ptau181) levels in the cerebro-spinal ﬂuid (CSF). 
 
2. Methods 
 
2.1. Sherlock integration analysis 
To identify genes with expression changes potentially contrib-uting to the etiology of LOAD, we 
integrated the eQTL of LCLs and GWAS data of LOAD using a Bayesian statistical framework, named 
Sherlock (http://sherlock.ucsf.edu/submit.html)(He et al., 2013). The statistical model and threshold 
setting can be found in the original article (He et al., 2013) and Supplementary materials. 
 
2.2. Analysis of eQTL and LOAD GWAS data 
The eQTL data set used in the discovery stage was reported previously (Dixon et al., 2007), which 
consisted of 400 LCL samples. More information about sample description, genotyping, tran-
scriptome proﬁling, and statistical analyses can be found in the original article (Dixon et al., 2007). 
The Alzheimer Disease Genetics Consortium (ADGC) reported a GWAS of LOAD investigating 
2,046,563 SNPs using a 3-stage design consisting of a discovery stage and 2 replication stages, which 
identiﬁed 5 novel risk loci for LOAD (Naj et al., 2011). In the discovery stage, the ADGC performed a 
meta-analysis and/or joint analysis using data from 9 case-control cohorts, consisting of 8309 
individuals with LOAD and 7366 cognitively normal age-/gender-matched controls. We used the 
summary statistics (p-values) from the discovery stage as input in our study. 
 
 
 
Fig. 1. Overview of research strategy. The strategy is based on the hypothesis that there may be 
variants that affect LOAD risk by inﬂuencing gene expression, and such variants would be associated 
with both AD risk and gene expression levels. We systematically integrated LOAD GWAS and eQTL 
data with the Sherlock algorithm. The top signals identiﬁed by Sherlock were then replicated in 
independent LOAD and eQTL data sets. We also tested whether the positive risk SNP, rs2927438, 
modiﬁed LOAD risk independent of APOE ε4 status. Finally, we explored its association with several 
endophenotypes, including AAO of LOAD, hippocampal volume, and cognitive per-formance. 
Abbreviations: AAO, age at onset; AD, Alzheimer’s disease; eQTL, expression quantitative trait loci; 
LOAD, late-onset Alzheimer’s disease; GWAS, genome-wide association study; SNP, single-nucleotide 
polymorphism. 
2.3. The follow-up of eQTL and LOAD GWAS results 
 
The following well-characterized expression data sets were used to validate the gene expression 
results that contributed to the identiﬁcation of functional LOAD-related eSNPs: (1) SNPExpress data 
set (brain frontal cortex, N ¼ 93; peripheral blood mono-nuclear cells [PBMC], N ¼ 80) (Heinzen et 
al., 2008); (2) meta-analysis of blood eQTL by Westra et al. (N ¼ 5311) (Westra et al., 2013); (3) GTEx 
data set (53 different tissues, including 12 brain tissues, N ¼ 544) (GTEx-Consortium, 2015); (4) 
BrainCloud (dorsolateral prefrontal cortex, N ¼ 261) (Colantuoni et al., 2011); and (5) Brain cortex 
data (Myers et al., 2007)(N ¼ 193). Detailed information can be found in supplementary data and the 
original articles (Colantuoni et al., 2011; GTEx-Consortium, 2015; Heinzen et al., 2008; Myers et al., 
2007; Westra et al., 2013). We used the largest reported GWAS meta-analysis of LOAD as a 
replication data set, which consisted of 17,008 cases and 37,154 controls (Lambert et al., 2013), 
including the ADGC data set used in our discovery stage. Detailed information on each data set, 
including diagnostic assessment, genotyping method, and quality control can be found in the original 
article (Lambert et al., 2013). 
We conducted bioinformatics analyses, including functional prediction, and linkage analysis between 
the risk SNPs and rs429358 or rs7412 underlying the ε2, ε3, and ε4 APOE alleles. In addition, we 
analyzed the association of the risk eSNP with hip-pocampal volume, as well as CSF levels of Ab42, 
tau, and ptau181. Detailed description of the methodology can be found in the supplementary 
methods. 
 
3. Results 
 
3.1. Integrative analyses of eQTL and LOAD GWAS Sherlock integrated the eQTL of LCLs (N ¼ 400) 
and GWAS data (2,046,563 SNPs) from 8309 LOAD cases and 7366 controls (Naj et al., 2011) using a 
Bayesian statistical framework, and identiﬁed 71,323 SNPs showing signiﬁcant eQTL effects. After 
implementing genetic signature matching from eQTL data with patterns of asso-ciation in the GWAS, 
we ranked potential LOAD risk genes accord-ing to their logarithm of Bayes factor (LBF) and p-value. 
The integrative analysis yielded 10 candidate LOAD genes with both LBF scores >4.0 and p-value <1.0 
E�04, which is the threshold applied in the original article (He et al., 2013)(Table 1). Among these 
genes, both bridging integrator 1 (BIN1) on chromosome 2q14.3 and biogenesis of lysosomal 
organelles complex 1 subunit 3 (BLOC1S3) on chromosome 19q13.32 have been associated with 
LOAD in previous GWAS and follow-up studies (Chapuis et al., 2013; Cruchaga et al., 2011; Seshadri 
et al., 2010). We therefore excluded these 2 genes from further analysis. The ﬁrst-ranked gene was 
ZNF257 (ZNF257 zinc ﬁnger protein 257; LBF ¼ 5.23), which is located on chromosome 19p12. 
Intriguingly, 5 genes on chromo-some 19q13 are inﬂuenced by the same eSNP (rs2927438) in a cis-
regulatory manner: EML2 (echinoderm microtubule associated protein like 2; LBF ¼ 5.17), ZNF226 
(zinc ﬁnger protein 226; LBF ¼ 5.00), PVRL2 (also known as NECTIN2, nectin cell adhesion molecule 
2; LBF ¼ 4.67); KLC3 (kinesin light chain 3; LBF ¼ 4.61); and ZNF222 (zinc ﬁnger protein 222; LBF ¼ 
4.56). To the best of our knowledge, this SNP has never been reported in genetic association studies 
of LOAD. The remaining 2 genes, RFFL (ring ﬁnger and FYVE-like domain containing E3 ubiquitin 
protein ligase; LBF ¼ 5.22) and LRRC46 (leucine-rich repeat containing 46 proteins; LBF ¼ 4.80) are 
inﬂuenced by trans-eSNPs (rs4726618 and rs4838429 for RFFL; rs8103315 and rs7743515 for 
LRRC46). 
 
3.2. Replication of eQTL effects 
Considering the many confounders in a single eQTL database, it is important to validate the eQTL 
associations in independent samples. 
For the cis-eSNP rs417628, we were unable to validate its asso-ciation with ZNF257 expression in the 
replication data set due to the absence of either the genotypic data for rs417628 or the expression 
data of ZNF257 (Supplementary table S1). Nevertheless, as demonstrated by a previous study (Puig 
et al., 2015), 1 breakpoint may disrupt the ZNF257 locus, causing a signiﬁcant reduction in the total 
expression level of this gene in LCLs. We thus excluded the association of rs417628 with ZNF257 
expression in further analysis. None of the trans-eQTL associations (RFFL and LRRC46) could be 
replicated (Supplementary table S1) and were also excluded from further study. Notably, trans-eQTL 
is more likely to reﬂect an indi-rect relationship of the SNP on gene expression. A gene’s trans 
perturbation may come from the mutation of a regulatory RNA, but this mutation may also affect 
multiple other genes. More impor-tantly, trans-eQTL is usually much weaker than those in cis and 
suffers from greater multiple testing burden, resulting in lower replication across multiple studies 
(Cheung et al., 2010). 
For rs2927438, we ﬁrst validated its cis-regulatory effect on the abovementioned candidate genes in 
SNPExpress, which contains expression data from both brain frontal cortical tissues and PBMC 
samples (Heinzen et al., 2008). With the exception of EML2, the results conﬁrmed the association of 
rs2927438 with the expression of ZNF226 (PBMC, p ¼ 0.0084), PVRL2 (PBMC, p ¼ 0.0024), KLC3 (p ¼ 
0.0037), and ZNF222 (a trend of association, p ¼ 0.0795)(Fig. 2), with the risk A-allele predicting 
higher gene expression for ZNF226, PVRL2, and ZNF222 and lower expression for KLC3. In the brain 
cortical tissue, rs2927438 was not signiﬁcantly associated with the expression of ZNF226, PVRL2, 
KLC3, ZNF222, and EML2 (Supplementary ﬁg. S1). Using another peripheral blood eQTL data set (N ¼ 
5311) (Westra et al., 2013), we further validated the as-sociation of rs2927438 with PVRL2 mRNA 
levels (p ¼ 3.66 E�05); again, the A-allele was associated with higher gene expression. 
We also tested whether rs2927438 was associated with the expression of these 5 genes in 13 brain 
tissues using the GTEx database (GTEx-Consortium, 2015). As shown in Supplementary ﬁg. S2, we 
observed signiﬁcant association of rs2927438 with expres-sion of PVRL2 in the accumbens (p ¼ 
0.033) and KLC3 in the hippocampus (p ¼ 0.047), and a trend of association with EML2 in the 
caudate (p ¼ 0.093). Collectively, these data provide strong evidence of the cis-regulatory function of 
rs2927438. 
 
Table 1 
Results of integrative analysis (Sherlock) of LOAD GWAS and eQTL 
 
 
  
 
 
 
3.3. Replication of association between rs2927438 and LOAD risk 
Similar to our validation of the eQTL results, we attempted to validate the association of rs2927438 
with LOAD. Using the largest GWAS meta-analysis of LOAD (17,008 cases and 37,154 controls, 
partially overlapping with the ADGC discovery data set) (Lambert et al., 2013), we observed 
signiﬁcant association between the A-allele of rs2927438 and increased risk of LOAD (p ¼ 5.69 E�29, 
OR ¼ 1.236). It might be an authentic LOAD variant because the increase in sample size of the 
replication cohort generated a much more signiﬁcant result (p ¼ 5.69 E�29) than the smaller 
discovery data set (p ¼ 1.05 E�07). Of note, the original study did not report this SNP because all 
SNPs within/ﬂanking the APOE locus were excluded due to the common presumption that the 
association signal in this region is APOE dependent (Lambert et al., 2013). In contrast, our LD 
analyses discussed below revealed that the association of LOAD with rs2927438 is likely APOE 
independent (Supplementary table S2).  
 
3.4. Pleiotropic analyses for rs2927438 
 
We explored whether rs2927438 is also associated with other human traits. A query of the National 
Human Genome Research Institute-European Bioinformatics Institute (NHGRI-EBI) catalog of 
published GWASs for rs2927438 revealed that the only entry listed was a suggestive GWAS signal for 
the increased risk of Barrett’s esophagus and esophageal adenocarcinoma (combined) with the G-
allele of rs2927438 (p ¼ 2.0 E�06, OR ¼ 1.16, 95% conﬁdence interval ¼ 1.10e1.25) (Levine et al., 
2013). In contrast, LOAD risk was associated with the A-allele. 
We further tested whether rs2927438 showed any association with the expression of nearby genes 
in the esophagus. Based on the expression data from the GTEx, we found signiﬁcant association for 
rs2927438 with PVRL2 expression (p ¼ 0.021) and marginal asso-ciation with EML2 expression (p ¼ 
0.055) in esophagus muscularis (Supplementary ﬁg. S3). Again, the G-allele predicted higher 
expression for both EML2 and PVRL2. 
 
3.5. rs2927438 represents an APOE-independent risk locus of LOAD on 19q13.32 
 
Because rs2927438 maps to an LD region on chromosome 19q13.32 signiﬁcantly associated with 
LOAD, and is located w170 kb upstream of APOE, we tested whether the observed association of 
rs2927438 with LOAD was APOE dependent. First, we checked whether rs2927438 was in LD with 
the 2 SNPs responsible for the APOE ε2, ε3, and ε4 alleles (rs429358 and rs7412) according to 
population data from the 1000 Genomes Project (phase 3). Haplo-view analyses of SNPs within a 
300-kb region encompassing rs2927438 and the 2 APOE SNPs (Supplementary table S2) showed 
weak LD of rs2927438 with both rs429358 and rs7412 in all 26 different subpopulations of European, 
African, Admixed-American, East Asian, and South Asian background (r2 � 0.07 and logarithm of the 
odds (LOD) score �1.5). Second, we explored whether there is a chromatin interaction between the 
genomic region containing rs2927438 and APOE using published data (Dixon et al., 2012) because 
recent studies showed that chromatin interactions play an important role in regulating gene 
expression (Pope et al., 2014). When using rs2927438 as bait, potential chromatin interactions 
(topologically associated domains) were observed only between rs2927438 and a 100-kb genomic 
region not affecting APOE (Supplementary ﬁgs. S4 and S5). Third, we tested whether APOE 
expression was affected by rs2927438 genotype in both blood and brain tissue. No signiﬁcant 
association between rs2927438 and APOE expression was observed in any of the expression data 
sets (Supplementary table S3). Taken together, these lines of evidence strongly suggest that 
rs2927438 may confer risk for LOAD inde-pendent of APOE. 
 
3.6. Effect of rs2927438 on AAO of LOAD, hippocampal volume, Ab42, tau and ptau181 levels 
 
We investigated if there have been any reports on the rela-tionship between rs2927438 and AAO of 
LOAD. Interestingly, the protective G-allele of this SNP revealed signiﬁcant association with delayed 
AD onset (p ¼ 1.39 E�12), according to a genome-wide survival analysis of 14,046 AD cases and 
25,849 controls (Huang et al., 2017). Furthermore, there was a report of an association between 
rs2927438 and human hippocampal volume, which may modify risk for developing LOAD 
(Apostolova et al., 2006). Using the ENIGMA 2 data set (N ¼ 33,536) (Hibar et al., 2017), we also 
observed a trend of association between the A-allele of rs2927438 and a smaller hippocampal 
volume (p ¼ 0.107, b ¼�1.61), consis-tent with previous observations of hippocampal atrophy in 
LOAD patients (Supplementary table S4). 
Genetic variants that increase risk for LOAD could also modify Ab42, tau and ptau181 levels in the 
CSF, which are used as endo-phenotypes of LOAD (Deming et al., 2017). Hence, we tested whether 
rs2927438 was associated with Ab42, tau and ptau181 levels in the CSF using published samples (N 
¼ 3146) (Deming et al., 2017). Signiﬁcant association was observed only between rs2927438 and tau 
levels (b ¼ 0.015, p ¼ 0.037), with the risk A-allele showing higher CSF tau levels (Supplementary 
table S5). 9q13 also exhibited signiﬁcant association with LOAD, that is, rs6859 in PVRL2 (Carrasquillo 
et al., 2009), rs4420638 in APOC1 (Li et al., 2008), rs59007384 and rs10524523 (poly-T poly-
morphism) in TOMM40 (Cervantes et al., 2011; Roses et al., 2010). The risk region around the APOE 
locus may be explained either by the strong LD with the APOE ε4 allele (Jun et al., 2012) or genetic 
variations in regulatory regions affecting APOE expression. How-ever, this may not be the case for 
rs2927438, which showed weak LD with APOE across all 26 subpopulations available at the 1000 
Genomes Project. Furthermore, no signiﬁcant association between rs2927438 and APOE expression 
was observed in either blood or brain tissue across different data sets. Moreover, there were no 
chromatin interactions between the genomic region containing rs2927438 and the promoter or 
enhancer region of APOE according to Hi-C chromatin interaction analysis. 
In this study, we used the eQTL effect in blood-derived LCLs, which is not ideal as a proxy for the 
eQTL effect in the brain (Nica et al., 2011; Ramasamy et al., 2014). However, we gain power for 
genes that are ubiquitously expressed because of the use of a rela-tively large data set for eQTL 
analysis in LCLs (N ¼ 400) (Dixon et al., 2007) compared with the available brain eQTL data set (N ¼ 
193 cortical tissues) (Myers et al., 2007). In addition, the number of eSNPs (N ¼ 71,732) for the 
blood-derived samples was much larger than that for cortical brain tissue (N ¼ 21,940), which can 
greatly increase power of candidate gene identiﬁcation. Also, the speciﬁc tissue or cell type relevant 
to a trait or disease is often unknown. For AD, neurons in the brain are seemingly the most relevant 
cell type; however, several studies have highlighted the involvement of microglia, which originate 
from peripheral monocytes (El Khoury et al., 2007). Recent genetic and molecular studies have also 
indicated crucial roles for peripheral monocytes in AD pathogenesis (Tajuddin et al., 2016), and 
LOAD risk alleles are polarized for cis-eQTL effects in monocytes (Raj et al., 2014). Finally, eQTLs 
were inconsistently observed even among data sets focusing on the same brain tissue (McKenzie et 
al., 2014). For example, in 2 studies examining the prefrontal cortex (Colantuoni et al., 2011; Liu et 
al., 2010), the proportion of over-lapping eQTLs was less than 10% (McKenzie et al., 2014). 
Furthermore, we observed a trend of association between the rs2927438 A-allele and reduced 
hippocampal volume in healthy subjects. Previous studies have shown marked reductions in the 
volume of the hippocampus and amygdala in patients with overt LOAD compared to healthy elderly 
individuals (Jack et al., 1992). In addition, patients with mild cognitive impairment, who are at high 
risk of developing AD, also have smaller hippocampal volumes than healthy elderly people (Du et al., 
2001). Even before the ﬁrst occurrence of memory complaints, hippocampal atrophy can pre-dict 
subsequent development of AD (den Heijer et al., 2006). Although the p-value of association 
between rs2927438 and hip-pocampal volume did not achieve nominal statistical signiﬁcance (p ¼ 
0.107), it is not surprising, given that atrophy in the hippo-campus is age dependent; and the mean 
age of the samples included in the present study was far less than 65 years (Hibar et al., 2017). 
Further studies are warranted to investigate this association. 
There are additional limitations in the present study. First, other genes that did not meet our strict 
selection criteria for the inte-grative analysis of GWAS/eQTL data may also contribute to LOAD risk. 
Second, we cannot exclude the possibility that the association signal was actually caused by the 
hitchhiking effect of other caus-ative variants, such as rare missense mutations and copy-number 
variations. The results from whole-genome sequencing of a LOAD data set may provide a more 
complete survey. Third, most of the AD samples collected for meta-analysis are of European origin, 
and whether rs2927438 also contributes to AD susceptibility in other populations remains elusive. 
Fourth, although blood-related eQTL data sets have been extensively used in AD studies, we cannot 
exclude the possibility of other missing risk genes speciﬁc to brain function regulation, and further 
studies using high-coverage large brain eQTL data sets are necessary. Notably, during the revision of 
the current article, the GTEx consortium published a large study on the effect of genomic variability 
on gene expression across multiple human tissues (GTEx-Consortium et al., 2017), which is an 
extremely valuable resource for future eQTL studies. 
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